Table 3.
Factors associated with time to virologic failure, stratified by HIV RNA viral load at INSTI initiation.
| Characteristic at INSTI initiation | Viral Load ≥50 | Viral Load <50 | ||
|---|---|---|---|---|
| Unadjusted HR1 (95% CI) | Adjusted HR2 (95% CI) | Unadjusted HR1 (95% CI) | Adjusted HR2 (95% CI) | |
| INSTI regimen | ||||
| EVG/COBI with ≥2 NRTI | 1 (ref.) | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| RAL with ≥2 NRTI | 0.43 (0.22, 0.81) | 0.35 (0.18, 0.68) | 0.63 (0.23, 1.75) | 0.77 (0.27, 2.23) |
| DTG with ≥2 NRTI | 0.68 (0.37, 1.25) | 0.80 (0.42, 1.50) | 0.08 (0.01, 0.60) | 0.11 (0.01, 0.80) |
| RAL with PI | 1.10 (0.65, 1.85) | 0.59 (0.33, 1.08) | 0.78 (0.22, 2.75) | 1.03 (0.26, 4.10) |
| Other | 1.22 (0.73, 2.03) | 0.76 (0.41, 1.39) | 0.51 (0.12, 2.23) | 0.89 (0.18, 4.36) |
| Sexual risk group | ||||
| MSM | 0.74 (0.48, 1.16) | 0.58 (0.35, 0.93) | 0.74 (0.26, 2.09) | 0.61 (0.20, 1.83) |
| Women | 1.09 (0.70, 1.68) | 0.79 (0.49, 1.25) | 1.53 (0.58, 4.02) | 1.35 (0.50, 3.61) |
| Heterosexual men | 1 (ref.) | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| African American race | 1.41 (0.97, 2.06) | 1.13 (0.77, 1.68) | 1.55 (0.72, 3.38) | 1.25 (0.53, 2.96) |
| Age, per 10-year increase | 0.84 (0.73, 0.98) | 0.74 (0.61, 0.89) | 0.68 (0.49, 0.94) | 0.67 (0.46, 0.98) |
| CD4, per 100-cell increase | 0.78 (0.72, 0.85) | 0.82 (0.75, 0.91) | 0.95 (0.84, 1.08) | 0.96 (0.84, 1.10) |
| Number of prior ARVs, per 1-drug increase | 1.06 (1.02, 1.11) | 1.07 (1.01, 1.12) | 0.97 (0.86, 1.09) | 0.99 (0.86, 1.12) |
| HIV RNA, per log10 increase | 1.35 (1.16, 1.57) | 1.14 (0.96, 1.34) | N/A | N/A |
Abbreviations. ARV: antiretroviral. CI: confidence interval. COBI: cobicistat. EVG: elvitegravir. DTG: dolutegravir. HR: hazard ratio. INSTI: integrase strand transfer inhibitor. MSM: men who have sex with men. N/A: not applicable. RAL: raltegravir. Ref.: referent. VL: viral load.
1
Estimates from separate Cox proportional models including only one characteristic.
2
Estimates from Cox proportional hazards models including all variables in the table, except HIV RNA for patients with baseline VL<50.